Ustekinumab biosimilar is under clinical development by Rani Therapeutics and currently in Phase I for Psoriasis. According to GlobalData, Phase I drugs for Psoriasis have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Ustekinumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Ustekinumab biosimilar overview
Ustekinumab biosimilar is under development for the treatment of psoriasis, psoriatic arthritis, ulcerative colitis, crohn’s disease. The drug candidate is an human IgG1kappa monoclonal antibody. It is administered through oral route in the form of capsule. It acts by targeting the p40 subunit of the cytokines IL-12 and IL-23. It is being developed based on RaniPill platform.
Rani Therapeutics overview
Rani Therapeutics, a subsidiary of Rani Therapeutics Holdings Inc, is a biotechnology company. It delivers a large drug molecules, including peptides, proteins, and antibodies. The company’s main innovation is the RaniPill™ capsule, a technology designed to replace injectable drugs with oral alternatives. Its product’s therapeutic areas include neuroendocrine tumors (NETs), acromegaly, osteoporosis, psoriatic arthritis, hypoparathyroidism and psoriasis. Rani Therapeutics’ pipeline products include RT-101, RT-102, RT-105, RT-110 and RT-111. It also provides medical researches. The company serves biologic drugs worldwide. Rani Therapeutics is headquartered in San Jose, California, US.
For a complete picture of Ustekinumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
